169 related articles for article (PubMed ID: 28584252)
1. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
Martínez-Cuadrón D; Montesinos P; Vellenga E; Bernal T; Salamero O; Holowiecka A; Brunet S; Gil C; Benavente C; Ribera JM; Pérez-Encinas M; De la Serna J; Esteve J; Rubio V; González-Campos J; Escoda L; Amutio ME; Arnan M; Arias J; Negri S; Lowënberg B; Sanz MA
Leukemia; 2018 Jan; 32(1):21-29. PubMed ID: 28584252
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
Montesinos P; González JD; González J; Rayón C; de Lisa E; Amigo ML; Ossenkoppele GJ; Peñarrubia MJ; Pérez-Encinas M; Bergua J; Debén G; Sayas MJ; de la Serna J; Ribera JM; Bueno J; Milone G; Rivas C; Brunet S; Löwenberg B; Sanz M
J Clin Oncol; 2010 Aug; 28(24):3872-9. PubMed ID: 20625122
[TBL] [Abstract][Full Text] [Related]
5. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
[TBL] [Abstract][Full Text] [Related]
7. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
8. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Sanz MA; Montesinos P; Vellenga E; Rayón C; de la Serna J; Parody R; Bergua JM; León A; Negri S; González M; Rivas C; Esteve J; Milone G; González JD; Amutio E; Brunet S; García-Laraña J; Colomer D; Calasanz MJ; Chillón C; Barragán E; Bolufer P; Lowenberg B
Blood; 2008 Oct; 112(8):3130-4. PubMed ID: 18664623
[TBL] [Abstract][Full Text] [Related]
10. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
Montesinos P; Bergua JM; Vellenga E; Rayón C; Parody R; de la Serna J; León A; Esteve J; Milone G; Debén G; Rivas C; González M; Tormo M; Díaz-Mediavilla J; González JD; Negri S; Amutio E; Brunet S; Lowenberg B; Sanz MA
Blood; 2009 Jan; 113(4):775-83. PubMed ID: 18945964
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA; Montesinos P; Rayón C; Holowiecka A; de la Serna J; Milone G; de Lisa E; Brunet S; Rubio V; Ribera JM; Rivas C; Krsnik I; Bergua J; González J; Díaz-Mediavilla J; Rojas R; Manso F; Ossenkoppele G; González JD; Lowenberg B;
Blood; 2010 Jun; 115(25):5137-46. PubMed ID: 20393132
[TBL] [Abstract][Full Text] [Related]
12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia.
Sanz MA; Montesinos P
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S130-4. PubMed ID: 21115431
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
Sanz MA; Vellenga E; Rayón C; Díaz-Mediavilla J; Rivas C; Amutio E; Arias J; Debén G; Novo A; Bergua J; de la Serna J; Bueno J; Negri S; Beltrán de Heredia JM; Martín G
Blood; 2004 Dec; 104(12):3490-3. PubMed ID: 15292063
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
16. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
17. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
18. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.
Montesinos P; Díaz-Mediavilla J; Debén G; Prates V; Tormo M; Rubio V; Pérez I; Fernández I; Viguria M; Rayón C; González J; de la Serna J; Esteve J; Bergua JM; Rivas C; González M; González JD; Negri S; Brunet S; Lowenberg B; Sanz MA
Haematologica; 2009 Sep; 94(9):1242-9. PubMed ID: 19608685
[TBL] [Abstract][Full Text] [Related]
20. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Tallman MS; Kim HT; Montesinos P; Appelbaum FR; de la Serna J; Bennett JM; Deben G; Bloomfield CD; Gonzalez J; Feusner JH; Gonzalez M; Gallagher R; Miguel JD; Larson RA; Milone G; Paietta E; Rayon C; Rowe JM; Rivas C; Schiffer CA; Vellenga E; Shepherd L; Slack JL; Wiernik PH; Willman CL; Sanz MA
Blood; 2010 Dec; 116(25):5650-9. PubMed ID: 20858857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
